Polybiomics

Polybiomics is a San Diego-based biotech firm founded in 2016, pioneering a novel live cell analysis platform. Its core technology allows for polysensing—the simultaneous measurement of multiple cellular parameters from a single sample without disrupting the 3D cellular environment—and leverages AI to interpret dynamic, multimodal data. The company targets a multi-billion dollar market by offering a modular system designed to improve efficiency and reproducibility across drug discovery, development, and biomanufacturing. With a strong scientific advisory board and a private, likely pre-revenue status, Polybiomics is positioned as a technology enabler in the life sciences tools and diagnostics sector.

Proprietary live cell analysis platform enabling simultaneous, continuous, multi-parameter measurement (polysensing) without disrupting 3D cellular environments. Integrates multimodal data with AI analytics to generate actionable insights for research, biopharma, biomanufacturing, and clinical workflows.

Polybiomics competes in the high-content analysis and live-cell imaging market against giants like Thermo Fisher Scientific, Danaher (through subsidiaries like Beckman Coulter and Leica), and PerkinElmer, as well as specialized players like Sartorius (Incelligence), Molecular Devices, and Nikon. Its differentiation lies in its claimed ability for simultaneous polysensing and continuous monitoring within 3D environments, a niche not fully addressed by current endpoint-focused or single-parameter systems.